IDO-Independent Suppression of T Cell Effector Function by IFN-γ–Licensed Human Mesenchymal Stromal Cells
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Human bone marrow–derived mesenchymal stromal cells (MSCs) inhibit proliferation of activated T cells, and IFN-γ plays an important role in this process. This IFN-γ–licensed veto property is IDO-dependent. To further decipher the mechanistic underpinnings of MSC veto function on T cells, we investigated the effect of MSCs and IFN-γ–licensed MSCs on T cell effector function as assayed by cytokine secretion of T cells. Although MSCs and IFN-γ–licensed MSCs inhibit T cell proliferation, only IFN-γ–licensed MSCs significantly inhibit Th1 cytokine (IFN-γ, TNF-α, and IL-2) production by T cells. Additionally, IFN-γ–licensed MSCs inhibit T cell degranulation as well as single, double, and triple cytokine–producing T cells. Although IFN-γ–licensed MSCs upregulate their IDO activity, we found that MSC IDO catalytic function is dispensable with regard to MSC-driven inhibition of T cell effector function. Novel flow cytometry based functional screening of MSC-expressed, IFN-γ–licensed inhibitory molecules identified B7H1 and B7DC/PD1 pathways as essential effectors in blocking T cell function. Small interfering RNA–mediated blocking of B7H1 and B7DC reverses the inhibitory potential of IFN-γ–licensed MSCs on T cell effector function. Mechanistic analysis revealed that clustering of MHC and coinhibitory molecules are indispensable for the inhibitory effect of IFN-γ MSCs. Although exogenous IL-2 reverses B7H1-Ig–mediated inhibition of T cell proliferation, it does not affect the veto function of IFN-γ MSCs on both T cell proliferation and effector function. Our results reveal a new immunosuppressive property of IFN-γ–licensed MSCs that inhibits T cell effector function independent of IDO but through the ligands for PD1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study by Chinnadurai et al. elegantly showed that MSCs can inhibit PBMC proliferation through PD1/PD-L1 [48].”
In the citing paper
“IFN-γ-primed MSCs have demonstrated to block T cell proliferation in a dose-dependent manner and to abrogate the production of IFN-γ, IL-2 and TNF-α, three cytokines with a role in T cell-derived immune response [136].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [136]
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“M arrowmesenchymal stromal cells (MSCs) play a role in maintaining the hematopoietic niche, regulate marrow immune homeostasis, and can differentiate into bone, cartilage, and adipocytes as a mesenchymal progenitor pool (1, 2).”
BackgroundMesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746 · cited 1×
“The therapeutic potential of transfused MSCs has been demonstrated in animal models of experimental autoimmune encephalitis, diabetes, rheumatoid arthritis, myocardial infarction, acute lung injury, retinal degeneration, acute renal failure, and transplant rejection (9, 10).”
BackgroundDi Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226 · cited 1×
“Therefore, an analysis of MSC immune plasticity in response to exogenous IFN-g stimulation (6, 22) and how this serves as an immune checkpoint to T cell activity are of physiological and translational interest.”
MethodCentral Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067 · cited 1×
“Once naive T cells are exposed to an activation signal they proliferate, and a subset becomes effector T cells as manifested by cytokine secretion and degranulation, based on their memory status (23, 24).”
BackgroundLe Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734 · cited 1×
“In human phase II clinical trials, MSCs were shown to be effective in treating graft-versus-host disease (11), although study of an industrial MSC product in a phase III trial was negative (12–14).”
BackgroundFriedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970) · Cell Proliferation · doi:10.1111/j.1365-2184.1970.tb00347.x · Cited by 2,724 · cited 1×
“Although endogenous clonogenic marrow MSCs represent a small minority of all nucleated cells in marrow space, typically 1:100,000, these same cells possess a robust mitogenic potential when cultured ex vivo (3, 4).”
BackgroundThe Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundHeterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.
Friedenstein, A. J., Kv, P., KUROLESOVA, A. I., & Frolova, G. P. (1968) · PubMed · Cited by 1,921
HETEROTOPIC TRANSPLANTS OF BONE MARROW
FRIEDENSTEIN, A. J., PETRAKOVA, K. V., KUROLESOVA, A. I., & FROLOVA, G. P. (1968) · Transplantation · doi:10.1097/00007890-196803000-00009 · Cited by 1,699
Meisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004) · Blood · doi:10.1182/blood-2003-11-3909 · Cited by 1,646
Research works printed but not linked: 1
- Jeremias, 1998, TRAIL/Apo-2-ligand-induced apoptosis in human T cells, Eur. J. Immunol., 28, 143, 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3 · DOI · Paper page
Cited by
Challenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712
Immune modulation by mesenchymal stem cells
Jiang, W., & Xu, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12712 · Cited by 650
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies
Noronha, N. D. C., Mizukami, A., Caliári-Oliveira, C., Cominal, J. G., Rocha, J. L. M., Covas, D. T., Swiech, K., & Malmegrim, K. C. R. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1224-y · Cited by 623
“functions through the upregulation of programmed cell death-1 ligands (PDL-1), at the same time, but independently of IDO upregulation [20].”
BackgroundGalipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R. J., DeBruijn, J., Dominici, M., Fibbe, W. E., Gee, A. P., Gimble, J. M., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2015.11.008 · Cited by 520
Self-citationBianco, P. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013132 · Cited by 402
Davies, L. C., Heldring, N., Kadri, N., & Le Blanc, K. (2017) · Stem Cells · doi:10.1002/stem.2509 · Cited by 349
Song, R., Li, T., Ye, J., Sun, F., Hou, B., Saeed, M., Gao, J., Wang, Y., Zhu, Q., Xu, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202101155 · Cited by 308
Strategies for Bone Regeneration: From Graft to Tissue Engineering
Battafarano, G., Rossi, M., De Martino, V., Marampon, F., Borro, L., Secinaro, A., & Del Fattore, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031128 · Cited by 295
Di Trapani, M., Bassi, G., Midolo, M., Gatti, A., Takam Kamga, P., Cassaro, A., Carusone, R., Adamo, A., & Krampera, M. (2016) · Scientific Reports · doi:10.1038/srep24120 · Cited by 285
Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 252
Camilleri, E. T., Gustafson, M. P., Dudakovic, A., Riester, S. M., Garces, C. G., Paradise, C. R., Takai, H., Karperien, M., Cool, S., Sampen, H.-J. I., et al. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0370-8 · Cited by 240
Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach
Chinnadurai, R., Rajan, D., Qayed, M., Arafat, D., Garcia, M., Liu, Y., Kugathasan, S., Anderson, L. J., Gibson, G., & Galipeau, J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.013 · Cited by 204
“Bone marrow aspirates were subjected to a Ficoll density gradient to obtain mononuclear cells, as described previously (Chinnadurai et al., 2014).”
InfluentialSelf-citationTherapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles
Heldring, N., Mäger, I., Wood, M. J. A., Le Blanc, K., & Andaloussi, S. E. L. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.072 · Cited by 191
Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?
Haddad, R., & Saldanha-Araujo, F. (2014) · BioMed Research International · doi:10.1155/2014/216806 · Cited by 188
Klinker, M. W., Marklein, R. A., Lo Surdo, J. L., Wei, C.-H., & Bauer, S. R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617933114 · Cited by 180
“This suggests that morphology not only serves as a phenotypic readout for IFN-γ treatment, but could also play a direct role in the magnitude of the MSC immunosuppression response as IFN-γ signaling promotes production of immunomodulatory factors such as indoleamine 2,3-dioxygenase, prostaglandin E2, and IL-6 (20, 36,…”
BackgroundTranslational strategies and challenges in regenerative medicine
Dimmeler, S., Ding, S., Rando, T. A., & Trounson, A. (2014) · Nature Medicine · doi:10.1038/nm.3627 · Cited by 179
Lohan, P., Treacy, O., Griffin, M. D., Ritter, T., & Ryan, A. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01626 · Cited by 178
“While indoleamine 2,3-dioxygenase (IDO) activity was increased in these licensed MSC, its function was largely dispensable with regard to MSCdriven inhibition of T cell effector function (25).”
BackgroundPreconditioning of Human Mesenchymal Stem Cells to Enhance Their Regulation of the Immune Response
Saparov, A., Ogay, V., Nurgozhin, T., Jumabay, M., & Chen, W. C. W. (2016) · Stem Cells International · doi:10.1155/2016/3924858 · Cited by 170
Chinnadurai, R., Copland, I. B., Garcia, M. A., Petersen, C. T., Lewis, C. N., Waller, E. K., Kirk, A. D., & Galipeau, J. (2016) · Stem Cells · doi:10.1002/stem.2415 · Cited by 167
Self-citationGalland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
“PD-L1 expression is upregulated in MSCs by IFN-γ [237], and PD-L1/PD1 is involved in MSC regulation of T- and B-cell proliferation [238,239].”
BackgroundInteractions between MSCs and Immune Cells: Implications for Bone Healing
Kovach, T. K., Dighe, A. S., Lobo, P. I., & Cui, Q. (2015) · Journal of Immunology Research · doi:10.1155/2015/752510 · Cited by 164
“The authors declare that there is no conflict of interests regarding the publication of this paper.”
BackgroundEngineering the MSC Secretome: A Hydrogel Focused Approach
Wechsler, M. E., Rao, V. V., Borelli, A. N., & Anseth, K. S. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001948 · Cited by 161
Inflammation, mesenchymal stem cells and bone regeneration
Liu, H., Li, D., Zhang, Y., & Li, M. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1643-3 · Cited by 160
López-García, L., & Castro-Manrreza, M. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179531 · Cited by 151
“In particular, an increase in the expression of PD-L1 was observed after 12 h of exposure to this cytokine, and this trend was maintained at 24, 48, and 72 h [67,74,148] (Figure 4).”
BackgroundInfluentialImmunomodulatory Functions of Mesenchymal Stem Cells in Tissue Engineering
Li, H., Shen, S., Fu, H., Wang, Z., Li, X., Sui, X., Yuan, M., Liu, S., Wang, G., & Guo, Q. (2019) · Stem Cells International · doi:10.1155/2019/9671206 · Cited by 151
Pianta, S., Signoroni, P. B., Muradore, I., Rodrigues, M. F., Rossi, D., Silini, A. R., & Parolini, O. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9558-4 · Cited by 152
Lee, B.-C., & Kang, K.-S. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01920-3 · Cited by 123
Targeting regulated cell death in tumor nanomedicines
Zeng, Q., Ma, X., Song, Y., Chen, Q., Jiao, Q., & Zhou, L. (2021) · Theranostics · doi:10.7150/thno.67932 · Cited by 125
“induce ferroptotic cell death by inhibiting the expression of endogenous SLC7A11 and SLC3A2 proteins, and the formed LPO acts as a localization signal to promote the phagocytosis of tumor cells by dendritic cells (DCs), thereby eliciting the immunogenicity of tumor cells [92, 93].”
BackgroundMesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis
Sarsenova, M., Issabekova, A., Abisheva, S., Rutskaya-Moroshan, K., Ogay, V. B., & Saparov, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111592 · Cited by 138
Follin, B., Juhl, M., Cohen, S., Pedersen, A. E., Kastrup, J., & Ekblond, A. (2016) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2015.0532 · Cited by 113
Poggi, A., Varesano, S., & Zocchi, M. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00262 · Cited by 110
“Indeed, it has been shown that PD1 is involved in MSC immunoregulation of T and B cell proliferation (18, 221, 222).”
BackgroundDhere, T., Copland, I., Garcia, M., Chiang, K. Y., Chinnadurai, R., Prasad, M., Galipeau, J., & Kugathasan, S. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13717 · Cited by 109
“PBMCs were cultured at 500 000 cells/well in a 24 well-plate with cultured 10% FBS RPMI and were stimulated using anti-CD3/anti-CD28 Dyna beads (Invitrogen Carlsbad, CA, USA) in the presence and absence of mesenchymal stromal cells at the indicated ratios, Co-culture of mesenchymal stromal cells and T cells for prolif…”
MethodSelf-citationBárcia, R. N., Santos, J. M., Filipe, M., Teixeira, M., Martins, J. P., Almeida, J., Água-Doce, A., Almeida, S. C. P., Varela, A., Pohl, S., et al. (2015) · Stem Cells International · doi:10.1155/2015/583984 · Cited by 108
Kota, D. J., Prabhakara, K. S., Toledano-Furman, N., Bhattarai, D., Chen, Q., DiCarlo, B., Smith, P., Triolo, F., Wenzel, P. L., Cox, C. S., et al. (2017) · Stem Cells · doi:10.1002/stem.2603 · Cited by 105
Ni, K., Liu, M., Zheng, J. H., Wen, L., Chen, Q., Xiang, Z., Lam, K.-T., Liu, Y., Chan, G., Lau, Y., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0326oc · Cited by 111
“PD-1/PD-L1 Pathway Contributed to Alleviation of Pulmonary Fibrosis by Human MSCs Researchers in a previous study found that PD-L1 expressed on human MSCs contributed significantly to their immunomodulatory capacity in in vitro experiments by targeting the PD-1–expressing T cells (Figure E4A) (33).”
García, J. R., Quirós, M., Han, W. M., O'Leary, M. N., Cox, G. N., Nusrat, A., & García, A. J. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119403 · Cited by 103
Varkouhi, A. K., Jerkić, M., Ormesher, L., Gagnon, S., Goyal, S., Rabani, R., Masterson, C. H., Spring, C., Chen, P., Gu, F., et al. (2019) · Anesthesiology · doi:10.1097/aln.0000000000002655 · Cited by 110
Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts
Najar, M., Krayem, M., Merimi, M., Burny, A., Meuleman, N., Bron, D., Raicevic, G., & Lagneaux, L. (2018) · Inflammation Research · doi:10.1007/s00011-018-1131-1 · Cited by 111
“In contrast, two studies have indicated that inflammatory primed BM-MSCs could exert their immunomodulatory functions independently of IFN-γ receptor 1 signaling and IDO expression and this may partially accounted for IGFbinding proteins [115] or through the induction of ligands for programmed cell death 1 (PD-1) such…”
ResultImmunosuppressive Property of MSCs Mediated by Cell Surface Receptors
Liu, S., Liu, F., Zhou, Y. L., Jin, B., Sun, Q., & Guo, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01076 · Cited by 110
Yan, L., Zheng, D., & Xu, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01658 · Cited by 111
Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer
O’Malley, G., Treacy, O., Lynch, K., Naicker, S. D., Leonard, N. A., Lohan, P., Dunne, P. D., Ritter, T., Egan, L. J., & Ryan, A. E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0443 · Cited by 109
“The inflammatory tumor secretome induces PD-L1 expression on stromal cells Stromal cells have been shown to inhibit T-cell responses by both cell contact–dependentmechanisms, via cell-surface protein expression, and cell contact–independent mechanisms, via release of soluble mediators (28, 29).”
BackgroundCommitment to Aerobic Glycolysis Sustains Immunosuppression of Human Mesenchymal Stem Cells
Liu, Y., Yuan, X., Munoz, N. M., Logan, T. M., & Ma, T. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0070 · Cited by 108
Li, W., Liu, Q., Shi, J., Xu, X. M., & Xu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1074863 · Cited by 132
“Resting mouse MSCs constitutively express low levels of COX-2, PGE-2, TGF-b1, HGF (23) and B7H1 (24), meanwhile resting human MSCs can persistently express ICAM-1 (25), CXCL10 (26), IL-6 (26), IL-8 (27), CCL-2 (28), PD-L1 (29), MHC I (30) and IDO (31).”
BackgroundA reproducible immunopotency assay to measure mesenchymal stromal cell–mediated T-cell suppression
Bloom, D. D., Centanni, J. M., Bhatia, N., Emler, C. A., Drier, D., Leverson, G. E., McKenna, D. H., Gee, A. P., Lindblad, R., Hei, D. J., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2014.10.002 · Cited by 92
“reasonable to anticipate that different preparations of MSCs exert various degrees of immunomodulation in diverse patient populations and clinical indications (34, 35).”
BackgroundGao, M., Guo, H., Dong, X., Wang, Z., Yang, Z., Shang, Q., & Wang, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1345779 · Cited by 140
“While inhibiting T cell effector activity, IFN-γ - sensitized MSCs also upregulate PDL-1, which increases the production of HLA molecules (Chinnadurai et al., 2014).”
BackgroundAuletta, J. J., Eid, S. K., Wuttisarnwattana, P., da Silva, I. P., Metheny, L. L., Keller, M. D., Guardia-Wolff, R., Liu, C., Wang, F., Bowen, T., et al. (2014) · Stem Cells · doi:10.1002/stem.1867 · Cited by 98
Galipeau, J. (2021) · Stem Cells · doi:10.1002/stem.3380 · Cited by 88
Self-citationRozenberg, A., Rezk, A., Boivin, M.-N., Darlington, P. J., Nyirenda, M., Li, R., Jalili, F., Winer, R., Artsy, E. A., Uccelli, A., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0243 · Cited by 88
CD 4 T cells in protection from influenza virus: Viral antigen specificity and functional potential
Sant, A. J., DiPiazza, A. T., Nayak, J. L., Rattan, A., & Richards, K. A. (2018) · Immunological Reviews · doi:10.1111/imr.12662 · Cited by 96
Krueger, T. E. G., Thorek, D. L. J., Meeker, A. K., Isaacs, J. T., & Brennen, W. N. (2018) · The Prostate · doi:10.1002/pros.23738 · Cited by 95
“MSC-mediated suppression of T-cell proliferation and effector functions.(81)”
Mesenchymal stem cells immunomodulation: The road to IFN-γ licensing and the path ahead
Carvalho, A. É. S., Sousa, M. R. R., Alencar-Silva, T., Carvalho, J. L., & Saldanha-Araujo, F. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.05.006 · Cited by 77
Immunogenicity of Allogeneic Mesenchymal Stromal Cells: What Has Been Seen in Vitro and in Vivo ?
Consentius, C., Reinke, P., & Volk, H. (2015) · Regenerative Medicine · doi:10.2217/rme.15.14 · Cited by 93
Mesenchymal stem cells: Biological characteristics and application in disease therapy
Lou, S., Duan, Y., Nie, H., Cui, X., Du, J., & Yao, Y. (2021) · Biochimie · doi:10.1016/j.biochi.2021.03.003 · Cited by 88
Zimmermann, J. A., Hettiaratchi, M. H., & McDevitt, T. C. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0044 · Cited by 87
Pretreated Mesenchymal Stem Cells and Their Secretome: Enhanced Immunotherapeutic Strategies
Su, Y., Xu, C., Cheng, W., Zhao, Y., Sui, L., & Zhao, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021277 · Cited by 89
“IFN-γ (50 ng/mL) 72 h BM-MSCs IDO (independent)↑, B7H1, B7DC↑ T-cell proliferation and cytokines production in vitro T-cell proliferation↓ Th1 cytokine (IFN-γ, TNF-α and IL-2) ↓ T-cell degranulation↓ (B7H1 and B7DC/PD1) [43]”
BackgroundInfluentialGuan, Q., Li, Y., Shpiruk, T. A., Bhagwat, S., & Wall, D. A. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.02.003 · Cited by 81
Li, Y., Duan, Y., Li, Y., Gu, Y., Zhou, L., Xiao, Z., Yu, X., Cai, Y., Cheng, E., Liu, Q., et al. (2024) · Exploration · doi:10.1002/exp.20230117 · Cited by 94
Lynch, K., Treacy, O., Chen, X., Murphy, N., Lohan, P., Islam, M. N., Donohoe, E., Griffin, M. D., Watson, L., McLoughlin, S., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.023 · Cited by 77
O'Malley, G., Heijltjes, M., Houston, A. M., Rani, S., Ritter, T., Egan, L. J., & Ryan, A. E. (2016) · Oncotarget · doi:10.18632/oncotarget.11354 · Cited by 71
Biological Considerations in Scaling Up Therapeutic Cell Manufacturing
Cherian, D. S., Bhuvan, T., Meagher, L., & Heng, T. S. P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00654 · Cited by 82
“May 2020 | Volume 11 | Article 654 demonstrated to occur via ligands expressed by human and mouse MSCs that bind to programmed cell death protein-1 (PD-1) on activated T cells to provide an inhibitory signal (Augello et al., 2005; Chinnadurai et al., 2014).”
BackgroundBarrachina, L., Remacha, A. R., Lasheras, A. R., Vázquez, F. J., Albareda, J., Prades, M., Ranera, B., Zaragoza, P., Martín‐Burriel, I., & Rodellar, C. (2016) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2016.02.007 · Cited by 86
Serejo, T. R. T., Silva-Carvalho, A. É., Filiú-Braga, L. D. D. C., Neves, F. D. A. R., Pereira, R. W., Carvalho, J. L., & Saldanha‐Araújo, F. (2019) · Cells · doi:10.3390/cells8010022 · Cited by 73
“Among them, the activation and licensing of MSCs [6] with inflammatory cytokines such as INF-γ [7,8] and Toll-like receptor (TLR) agonists [9,10] has been heavily investigated.”
Wobma, H., Kanai, M., Ma, S. P., Shih, Y., Li, H. W., Duran‐Struuck, R., WINCHESTER, R. J., Goeta, S., Brown, L. M., & Vunjak‐Novakovic, G. (2018) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2018.01.001 · Cited by 88
Chinnadurai, R., Copland, I. B., Ng, S., Garcia, M. A., Prasad, M., Arafat, D., Gibson, G. C., Kugathasan, S., & Galipeau, J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.67 · Cited by 67
“Harvested bone marrow was separated by Ficoll density gradient and plated on α-MEM culture medium containing 10% human platelet lysate[27, 28] and 100 U/ml penicillin/streptomycin (200,000 cell/cm(2)).”
BackgroundMethodSelf-citationBravo, M. D. O., Carvalho, J. L., & Saldanha‐Araújo, F. (2016) · Purinergic Signalling · doi:10.1007/s11302-016-9529-0 · Cited by 70
Zhou, K., Guo, S., Tong, S., Sun, Q., Li, F., Zhang, X., Qiao, Y., & Liang, G. (2018) · Stem Cells and Development · doi:10.1089/scd.2018.0033 · Cited by 63
“PD-L1 and Gal-9 are coinhibitory molecules whose roles in the modulatory mechanisms of human PMSCs, BM-MSCs, and UCB-MSCs have been reported [18, 20-23, 36].”
Dalmızrak, A., & Dalmızrak, Ö. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.956563 · Cited by 63
Marinaro, F., Gómez‐Serrano, M., Jorge, I., Silla-Castro, J. C., Vázquez, J., Sanchez-Margallo, F. M., Blázquez, R., López, E., Álvarez, V., & Casado, J. G. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00431 · Cited by 67
“This idea has been studied by using Interferon gamma (IFNγ)-priming (DelaRosa et al., 2009; Chinnadurai et al., 2014; Liang et al., 2018), Toll-like receptors priming (Sangiorgi and Panepucci, 2016; Najar et al., 2017), and other inflammatory stimuli (Kim and Cho, 2016).”
MethodChinnadurai, R., Rajan, D., Ng, S., McCullough, K., Arafat, D., Waller, E. K., Anderson, L. J., Gibson, G., & Galipeau, J. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006205 · Cited by 60
Self-citationSoluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist
Ng, K. W., Attig, J., Young, G. R., Ottina, E., Papamichos, S. I., Kotsianidis, Ι., & Kassiotis, G. (2019) · eLife · doi:10.7554/elife.50256 · Cited by 63
“Early studies using recombinant sPD-L1 suggested an immune suppressive role either in inhibiting T cell activation or in promoting T cell apoptosis (Chinnadurai et al., 2014; Frigola et al., 2011).”
BackgroundCalcat-i-Cervera, S., Rendra, E., Scaccia, E., Amadeo, F., Hanson, V., Wilm, B., Murray, P., O’Brien, T., Taylor, A., & Bieback, K. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03352-1 · Cited by 56
“A study by Chinnadurai et al. elegantly showed that MSCs can inhibit PBMC proliferation through PD1/PD-L1 [48].”
BackgroundDifferential Efficacy of Human Mesenchymal Stem Cells Based on Source of Origin
Collins, E. L., Gu, F., Qi, M., Molano, I. D., Ruiz, P., Sun, L., & Gilkeson, G. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401636 · Cited by 61
Pollock, K., Samsonraj, R. M., Dudakovic, A., Thaler, R., Stumbras, A. R., McKenna, D. H., Dosa, P. I., van Wijnen, A. J., & Hubel, A. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0347 · Cited by 62
Hackel, A. M., Vollmer, S., Bruderek, K., Lang, S., & Brandau, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1078551 · Cited by 57
“The expression of PD-1 ligand 1 (PD-L1) is reported on non-hematopoietic cells, like MSCs, but also on hematopoietic cells, while PD-1 ligand 2 (PD-L2)-expression is typically found on antigen-presenting cells (APCs), but it is also found to be expressed by MSCs (37, 39, 40).”
BackgroundOzay, E. I., Vijayaraghavan, J., Gonzalez-Perez, G., Shanthalingam, S., Sherman, H. L., Garrigan, D. T., Chandiran, K., Torres, J. A., Osborne, B. A., Tew, G. N., et al. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101401 · Cited by 55
“Although numerous reports have correlated high IDO expression with potent MSC-mediated immune suppression, at least one report suggests that immune suppression can proceed in an IDO-independent manner, through PD-L1-PD1 signaling (Chinnadurai et al. 2014).”
BackgroundForbes, S., Bond, A. R., Thirlwell, K. L., Burgoyne, P., Samuel, K., Noble, J., Borthwick, G., Colligan, D., McGowan, N. W. A., Lewis, P. S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5907 · Cited by 54
“15 The ability to suppress T cell activation and express TGF-beta in the non-stimulated state has not previously been described for MSCs (40; 41) and is beneficial, along with the ability to upregulate pro-regenerative factors when induced by inflammation.”
BackgroundMennan, C., Brown, S. J., McCarthy, H. S., Mavrogonatou, E., Kletsas, D., Garcia, J., Balain, B., Richardson, J. B., & Roberts, S. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12104 · Cited by 58
Engineered anti-cancer nanomedicine for synergistic ferroptosis-immunotherapy
Zhang, X., Ge, H., Ma, Y., Song, L., Ma, Y., Tian, G., Wang, L., Meng, Q., & Sun, X. J. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.140688 · Cited by 52
Zhao, C., Zhang, L., Kong, W., Liang, J., Xu, X., Wu, H., Feng, X., Hua, B., Wang, H., & Sun, L. (2015) · Journal of Immunology Research · doi:10.1155/2015/137695 · Cited by 55
“IDO, HGF, and IL-10 are regulatory molecules secreted by UCMSC [24, 25], and we observed that levels of these factors were upregulated following coculture with FLS.”
BackgroundChallenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease
Chinnadurai, R., Ng, S., Velu, V., & Galipeau, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i16.4779 · Cited by 50
Self-citationAkhter, W., Nakhle, J., Vaillant, L., Garcin, G., Saout, C. L., Simon, M., Crozet, C., Djouad, F., Jørgensen, C., Vignais, M., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03219-x · Cited by 56
Liao, Y., Lei, J., Liu, M., Lin, W., Hong, D., Tuo, Y., Jiang, M. H., Xia, H., Wang, M., Huang, W., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.140 · Cited by 52
Lewis, H. C., Chinnadurai, R., Bosinger, S. E., & Galipeau, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20166 · Cited by 48
Self-citationChen, D., Tang, P., Liu, L., Wang, F., Xing, H., Sun, L., & Jiang, Z. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1442624 · Cited by 48
“It has been reported that MSCs inhibited T cell proliferation and effector function via contactdependent interactions of PD-1/PD-L1 in autoimmune disorders [27,28].”
BackgroundResponse of human periodontal ligament stem cells to IFN-γ and TLR-agonists
Andrukhov, O., Hong, J. S.-A., Andrukhova, O., Blufstein, A., Moritz, A., & Rausch‐Fan, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-12480-7 · Cited by 52
Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?
Dunavin, N., Dias, A., Li, M., & McGuirk, J. P. (2017) · Biomedicines · doi:10.3390/biomedicines5030039 · Cited by 49
“As seen with IDO and CD39, high PD-L1 expression in fetal tissues promotes immune tolerance at the maternal–fetal interface [79].”
BackgroundInfluentialLoisel, S., Dulong, J., Menard, C., Renoud, M.-L., Mézière, N., Bézier, I., Latour, M., Bescher, N., Pedeux, R., Bertheuil, N., et al. (2017) · Stem Cells · doi:10.1002/stem.2580 · Cited by 49
Ayenehdeh, J. M., Niknam, B., Rasouli, S., Hashemi, S. M., Rahavi, H., Rezaei, N., Soleimani, M., Liaeiha, A., Nicknam, M. H., & Tajik, N. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.05.006 · Cited by 44
Lim, J., Kim, B., Ryu, D., Kim, T. W., Park, G., & Min, C. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02087-7 · Cited by 51
“Previous studies demonstrated that MSC priming with pro-inflammatory cytokines, such as IFN-γ and TNF-α, increased the secretion of anti-inflammatory cytokines (IDO1, PGE2, TGF-β, and hepatocyte growth factor), the expression of chemokine ligands (CXCL9, CXCL10, and CXCL11), adhesion proteins (VCAM-1 and ICAM-1), and…”
BackgroundInfluentialKlein, D. (2016) · Stem Cells International · doi:10.1155/2016/1905846 · Cited by 45
CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells
Gaber, T., Schönbeck, K., Hoff, H., Tran, C. L., Strehl, C., Lang, A., Ohrndorf, S., Pfeiffenberger, M., Röhner, E., Matziolis, G., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082312 · Cited by 48
“An additio al mechanism described involves the expression of indoleamine 2,3-dioxygenase (IDO) in MSCs; however, the relevance of IDO for the inhibitory effect on T cells is still under discussion [42,43].”
BackgroundBeeken, L. J., Ting, D. S. J., & Sidney, L. E. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0118 · Cited by 45
“Although the mechanisms are not fully elucidated, suggested explanations include the upregulation of IDO, the clustering of MHC and co-inhibitory molecules, and epigenetic changes.(72,73) Additionally, priming the cells through hypoxia treatment and activation of the MSC nucleotide binding domain, as well as technique…”
MethodLi, Y., Jin, M., Guo, D., Shen, S., Lu, K., Pan, R., Sun, L. J., Zhang, H., Shao, J., & Pan, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117537 · Cited by 51
Ex Vivo Induced Regulatory Human/Murine Mesenchymal Stem Cells as Immune Modulators
Hinden, L., Shainer, R., Almogi‐Hazan, O., & Or, R. (2015) · Stem Cells · doi:10.1002/stem.2026 · Cited by 43
Das, R., Roosloot, R., van Pel, M., Schepers, K., Driessen, M., Fibbe, W. E., de Bruijn, J. D., & Roelofs, H. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1989-x · Cited by 47
Remestemcel-L for the treatment of graft versus host disease
Locatelli, F., Algeri, M., Trevisan, V, & Bertaina, A. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1208086 · Cited by 41
“During the whole process, the cytokine milieu of aGvHD exerts a key role in MSCs activation and polarization towards an anti-inflammatory phenotype, characterized by enhanced secretion of soluble factors, including IDO, PGE2, TGF-?, and up-regulation of surface inhibitory molecules, such as PD-L1. an attractive clinic…”
BackgroundPeltzer, J., Lund, K., Goriot, M., Grosbot, M., Lataillade, J., Mauduit, P., & Banzet, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.581436 · Cited by 49
Dissecting the relationship between antimicrobial peptides and mesenchymal stem cells
Silva-Carvalho, A. É., Cardoso, M. H. E. S., Alencar‐Silva, T., Bogéa, G. M. R., Carvalho, J. L., Franco, O. L., & Saldanha‐Araújo, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108021 · Cited by 43
Zhang, X., Liu, T., Ran, C., Wang, W., Piao, F., Yang, J., Tian, S., Li, L., & Zhao, D. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1411507 · Cited by 55
“…induce transplanted MSCs to release anti-in fl ammatory factors, thereby inhibiting the release of in fl ammatory factors by in fl ammatory immunocyt and reducing excessive in fl ammation (Francois et al., 2012; Noone et al., 2013; Chinnadurai et al., 2014; Croes et al., 2015; Noronha et al., 2019).”
Background
Metadata
- Authors
- Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J.
- Affiliations
- Emory University (US)
- Corresponding author
- Chinnadurai, Raghavan
- Galipeau, Jacques
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02
- Volume
- 192
- Issue
- 4
- Pages
- 1491-1501
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147854121
- Cited by
- 266
- References
- 63
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 15 · 2023: 30 · 2022: 15 · 2021: 28 · 2020: 31 · 2019: 19 · 2018: 22 · 2017: 25 · 2016: 24 · 2015: 21 · 2014: 10
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (T32AI007610)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- mesenchymal stem cells, T cell effector function, PD-L1, PD-1, T cell degranulation, interleukin-2, T cell proliferation inhibition, bone marrow-derived stromal cells
- MeSH terms
- Bone Marrow Cells, Cells, Cultured, Humans, Interferon-gamma, Interleukin-2, Lymphocyte Activation, Tumor Necrosis Factor-alpha, Cell Degranulation, Th1 Cells, RNA Interference, RNA, Small Interfering, Cell Proliferation, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mesenchymal Stem Cells, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.